Fusion Pharmaceuticals Inc (NAS:FUSN)

$ 21.55 0 (0%) Market Cap: 1.83 Bil Enterprise Value: 1.69 Bil PE Ratio: 0 PB Ratio: 7.56 GF Score: 36/100

Fusion Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Fusion Pharmaceuticals Inc To Present Interim Data Transcript
Jun 27, 2023
Fusion Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Fusion Pharmaceuticals Inc at Bloom Burton & Co Healthcare Investor Conference Transcript
Apr 25, 2023
Fusion Pharmaceuticals Inc To Acquire Phase 2 Program For 225Ac-PSMA I&T, A Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer Transcript
Feb 13, 2023
Fusion Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022
Fusion Pharmaceuticals Inc at Bloom Burton & Co. Healthcare Investor Conference Transcript
May 02, 2022
Fusion Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Fusion Pharmaceuticals Inc. - Special Call Transcript
Nov 02, 2020

Fusion Pharmaceuticals Inc To Acquire Phase 2 Program For 225Ac-PSMA I&T, A Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer Transcript

Feb 13, 2023 / 09:45PM GMT

Release Date Price: $3.62 (+5.23%)

Transcript

Operator

Hello, and welcome to the Fusion Conference Call. (Operator Instructions) Please note this event is being recorded.

I would now like to turn the conference over to Amanda Cray, Head of Investor Relations and Corporate Communications. Amanda, please go ahead.

Amanda Cray

Fusion Pharmaceuticals Inc. - Senior Director of IR & Corporate Communications

Thank you, MJ, and thank you all for joining today's call. Please note that we have slides we'll be referring to posted in the Events & Presentations section of the Fusion website.

With us from management on the call today are Chief Executive Officer, John Valliant; Chief Financial Officer, John Crowley; Chief Medical Officer, Dmitri Bobilev, Chief Technology Officer, Eric Burak; Chief Scientific Officer, Chris Leamon; and President and Chief Business Officer, Mohit Rawat.

In addition, we're pleased to welcome to the call, Dr. Oliver Sartor, Laborde Professor for Cancer Research, Medical Director of the Tulane Center -- Cancer Center, an Assistant Dean for oncology at Tulane

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.